Illumina secures drug discovery tie-ups with Janssen, Deerfield
Illumina has recently announced a 10-year-long strategic collaboration with Janssen Biotech, and a five-year partnership with Deerfield Management.
Archives for May 9, 2022
Simulation model shows potential clinical value of Eisai drug for patients with early AD
In a simulation model, lecanemab treatment was estimated to potentially slow the rate of disease progression, maintaining treated patients for a longer duration in earlier stages of mild cognitive impairment (MCI) due to early AD.
Swiss biotech R&D investments reach record high
Capital investments in Swiss biotech companies reached CHF 3.33bn ($3.53bn) in 2021; while R&D investments increased to a record-high CHF 2.56bn ($2.71bn).
Developing vaccines against Epstein-Barr virus
Last week the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, launched a clinical trial to investigate a preventative vaccine for Epstein-Barr virus (EBV). It’s part of growing efforts to...